🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07774143
Recruiting Not applicable

A Prospective, Multicenter, Randomized Controlled Trial Investigating the Impact of Fasting Duration on Postoperative Rebleeding Following Esophageal Variceal Ligation.

NCT07774143 · tracked via the Priya Life Science China tracker
Sponsor
The First Affiliated Hospital of Zhengzhou University
Phase
Not applicable
Started
2026-06-20
Last updated
2026-08-19

Condition(s) studied

Esophageal Varices

Investigational drug(s) / intervention(s)

fasting periods of 24 hoursfasting periods of 48 hoursfasting periods of 6 hours

fasting periods of 24 hours: Post-balloon occlusion procedure: fasting for 24 hours

fasting periods of 48 hours: Post-balloon occlusion procedure: fasting for 48 hours

fasting periods of 6 hours: Post-balloon occlusion procedure: fasting for 6 hours

Study summary

To evaluate the efficacy and safety of early postoperative oral intake (with a fasting period of 6 hours) versus delayed postoperative oral intake (with fasting periods of 24 hours or 48 hours) in patients with cirrhosis undergoing esophageal variceal ligation therapy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: -1. The patient must be aged\>18 years; 2. The diagnosis of portal hypertension must be confirmed, with gastroscopy revealing severe esophageal varices and a positive red sign; 3. For patients undergoing endoscopic variceal ligation (EVL) due to esophageal varices (including those with hemorrhage or those eligible for elective ligation), successful intraoperative ligation is achieved (achieving hemostasis or completing the predetermined ligation procedure). 4\. Sign the informed consent form Exclusion Criteria: * 1\. Uncontrolled active bleeding or concurrent bleeding from gastric fundal varices; 2.History of prior TIPS, EVL, or surgical shunt procedures; 3. Presence of severe systemic diseases, such as sepsis, uremia, or advanced hepatocellular carcinoma (HCC); 4.Mechanical ventilation with retained catheter, inability to take oral intake, or significant dysphagia, or a history of major esophageal/gastric surgery that has impaired swallowing function; 5. Severe hepatic failure: Child-Pugh score\>13; profound jaundice (serum bilirubin\>10 mg/dL) accompanied by altered consciousness beyond Stage II or massive ascites; 6.Pregnancy or lactation; 7. Inability to provide informed consent.

Primary outcome measure(s)

Trial sites (12)

FacilityCityRegionStatus
The Fifth People's Hospital of Anyang Anyang China Recruiting
The Secend People's Hospital of Jiaozuo Jiaozuo China Recruiting
Huaihe Hospital of Henan University Kaifeng China Recruiting
Luohe Central Hospital Luohe China Recruiting
Luoyang Central Hospital Luoyang China Recruiting
Nanyang Central Hospital Nanyang China Recruiting
Sanmenxia Central Hospital Sanmenxia China Recruiting
Shangqiu Municipal Hospital Shangqiu China Recruiting
The First Affiliated Hospital of Xinxiang Medical University Xinxiang China Recruiting
Xuchang Central Hospital Xuchang China Recruiting
the First Affiliated Hospital of Zhengzhou University Zhengzhou China Recruiting
Zhoukou Central Hospital Zhoukou China Recruiting

More The First Affiliated Hospital of Zhengzhou University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07774143 on ClinicalTrials.gov ↗ ← All trials in China